Description
Join the Midwest AETC for this webinar on transforming HIV prevention.
Objectives
- Describe HIV prevention options, including currently approved oral and injectable PrEP options.
- Explain the mechanism of action, pharmacokinetics, dosing, safety, and efficacy of cabotegravir and lenacapavir for PrEP.
- Compare the advantages and limitations of long-acting, injectable PrEP.
- Discuss the HIV PrEP pipeline, including longer-acting agents and novel delivery systems.
Speaker
Emily Drwiega, PharmD, BCIDP, BCPS, AAHIVP
Visiting Clinical Assistant Professor/Clinical Pharmacist
UIC College of Pharmacy